Stay updated on Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page
- ChecktodayChange DetectedThe webpage has updated its time slot availability by adding several new dates in 2025 and 2026 while removing some previously listed dates from late 2024.SummaryDifference0.5%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has been updated to reflect a new study involving the drug carboplatin and gemcitabine, replacing the previous focus on enfortumab vedotin. Key collaborators have been updated to include Merck Sharp & Dohme LLC and Seagen Inc.SummaryDifference20%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to December 27, 2024.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to version 2.14.3, replacing the previous estimated update date of December 27, 2024, and revision version 2.14.2.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
Stay in the know with updates to Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combinations in Urothelial Cancer Clinical Trial page.